Guilhem R.
- Country
- France
- Department
- Oncologie médicale
Research Overview
- SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer
- Phase I Study of XL092 Monotherapy and Combination Therapy in Advanced Solid Tumors: ccRCC, nccRCC, HR+ BC, mCRPC, and CRC
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
Data & Insights
Has run more than one trial at 302 of 556 partner sites.
Specializations
Prostate Cancer Research
This investigator specializes in advanced therapeutic approaches for various stages of prostate cancer, with particular focus on metastatic castration-resistant prostate cancer (mCRPC) and hormone-sensitive prostate cancer.
- Novel hormone therapy combinations
- Treatment strategies for high-risk localized disease
- Management of oligometastatic disease
Research interests include innovative treatment combinations and targeted therapies for prostate cancer progression.
Bladder Cancer Studies
The investigator conducts research in urothelial carcinoma and non-muscle invasive bladder cancer, exploring new therapeutic approaches and treatment combinations.
- Immunotherapy applications
- Novel targeted therapies
- Treatment strategies for advanced disease
Focus areas include innovative therapeutic combinations and treatment optimization for various stages of bladder cancer.
Advanced Cancer Therapeutics
Research encompasses broad therapeutic approaches in advanced solid tumors with emphasis on novel drug development and combination strategies.
- Targeted molecular therapies
- Treatment resistance mechanisms
- Clinical trial development
Investigation includes innovative treatment approaches and therapeutic combinations for various advanced cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.